Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 29,389	$ 10,596
Accounts receivable	8	157
Prepaid expenses and other current assets	916	533
Total current assets	30,313	11,286
Property and equipment, net	371	416
TOTAL ASSETS	30,684	11,702
Current liabilities:
Accounts payable	3,246	3,169
Accrued expenses	1,229	1,937
Senior secured convertible debt, net	2,294	8,074
Total current liabilities	6,769	13,180
Long-term debt	1,134	1,134
TOTAL LIABILITIES	7,903	14,314
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2021, and December 31, 2020; 28,445,806 and 22,388,027 shares issued as of March 31, 2021 and December 31, 2020, respectively; 28,444,954 and 22,387,175 shares outstanding as of March 31, 2021 and December 31, 2020, respectively	3	3
Additional paid-in capital	284,881	250,914
Treasury stock, at cost; 852 shares of common stock as of March 31, 2021 and December 31, 2020, respectively	(11)	(11)
Accumulated deficit	(284,055)	(277,481)
Total Vaccinex, Inc. stockholders’ equity (deficit)	818	(26,575)
Noncontrolling interests	21,963	23,963
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	22,781	(2,612)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 30,684	$ 11,702